- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04809103
Intratumoral Cisplatin for Resectable NSCLC
A Phase 1 Trial of Intratumoral Cisplatin for Early Stage, Resectable, Non-Small Cell Lung Cancer
PRIMARY OBJECTIVE:
To identify the maximum tolerated dose (MTD) of intratumoral cisplatin, delivered during a single bronchoscopy with cone-beam CT confirmation, in a dose escalation protocol
DESIGN: 3+3 dose escalation.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. Even for early stage disease, the rate of recurrence following surgical resection is as high as 50%. Although neoadjuvant therapy, administered before surgery, for early stage lung cancer is associated with a survival benefit, it is rarely used due to the systemic toxicity of intravenous (IV) cytotoxic chemotherapy. IV immunotherapies are also being evaluated in combination with systemic therapies in the neoadjuvant setting. However, only a minority of patients respond to immunotherapy. One of the most common reasons for failure of immunotherapy is lack of presentation of tumor antigens to the immune system, a problem that may be potentially addressed with cytotoxic agents.
Over the last several years, case series have demonstrated the feasibility and safety of delivering cisplatin directly into lung tumors. Given the current knowledge of safety and tolerability of intratumoral cisplatin, coupled with the potential to achieve immune priming that may help address systemic micrometastases, the investigators postulate that intratumoral cisplatin will be well-tolerated, and potentially effective, neoadjuvant therapy for patients with early stage, resectable, non-small cell lung cancer.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Ardren Sara
- Telefonnummer: 8026563795
- E-post: sara.ardren@uvmhealth.org
Studieorter
-
-
Vermont
-
Burlington, Vermont, Förenta staterna, 05405
- Rekrytering
- University of Vermont
-
Kontakt:
- Sara Ardren
- Telefonnummer: 802-656-3795
- E-post: sara.ardren@uvmhealth.org
-
Kontakt:
- C. Matthew Kinsey
- Telefonnummer: 8026563525
- E-post: Matt.Kinsey@uvmhealth.org
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥18 years.
- Eastern Cooperative Oncology Group performance status 0 or 1
Patients must have adequate organ and marrow function as defined below:
- Leukocytes ≥3,000/microliter
- Platelets ≥100,000/microliter
- Total bilirubin ≤ institutional upper limit of normal (ULN)
- Aspartate aminotransferase /Alanine aminotransferase ≤3 × institutional upper limit of normal
- Creatinine ≤ institutional ULN
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Have known or suspected clinical stage I-IIb NSCLC after computed tomography (CT) and/or positron emission tomography at time of enrollment
- Presence of a target lesion with a minimum volume of 1.0 cm3, (approximately1.2 cm in diameter) and ≤ 5.0 cm in diameter
- Agreement from a cardiothoracic surgeon, following review of past medical history, medications, pulmonary function testing, and CT scan that patient is likely to be a surgical candidate and that, after considering known possible adverse events, delivery of intratumoral cisplatin is unlikely to adversely affect surgical feasibility
- Rapid on-site cytopathologic examination (ROSE) performed during the procedure returns likely NSCLC (per the determination of a trained, attending, cytopathologist). No research procedures will be performed if ROSE is non-diagnostic
- A CT scan of the chest (with or without contrast) within 1 month of the screening visit
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Use of an investigational agent within 30 days of the screening visit
- IV chemotherapy within the 30 days of the screening visit
- Pregnancy/lactation (pregnancy test to be performed by pre-op as part of standard of care for women of child-bearing age as defined by University of Vermont Medical Center Policy
- History of prior radiation to the study lesion
- History of allergic reaction to cisplatin or its derivatives
- Patients with uncontrolled intercurrent illness
- Physician determination that patient would not be appropriate for study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Intratumoral Cisplatin Arm
Single arm approach.
There is no comparator or placebo group.
Cisplatin will be administered directly into a non-small cell lung cancer, following imaging verification and pathologic diagnosis, during a single bronchoscopic procedure.
|
Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Rate of dose limiting toxicity
Tidsram: Within 2 weeks of delivery
|
Adverse events as defined using the Common Terminology Criteria for Adverse Events
|
Within 2 weeks of delivery
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Major pathologic response
Tidsram: Assessed on the surgical resection specimen, performed within 30 days of bronchoscopic delivery
|
Evaluation of the tissue response to the drug
|
Assessed on the surgical resection specimen, performed within 30 days of bronchoscopic delivery
|
Blood biomarker panel
Tidsram: Assessed from blood drawn on day of bronchoscopy and day of surgical resection
|
Includes serum cytokine analysis, mass cytometry for inflammatory cells, and complete blood count
|
Assessed from blood drawn on day of bronchoscopy and day of surgical resection
|
Tissue biomarker panel
Tidsram: Assessed from tissue obtained on day of bronchoscopy and day of surgical resection
|
Includes evaluation of cellular constituents and sequencing of cells present in tissue
|
Assessed from tissue obtained on day of bronchoscopy and day of surgical resection
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: C. Matthew Kinsey, MD, MPH, University of Vermont
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 00001101
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Icke-småcellig lungcancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeRefraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Mogen T-cell och NK-cell non-Hodgkin lymfom | Återkommande moget T- och NK-cells non-Hodgkin-lymfom | Återkommande kutant T-cell non-Hodgkin lymfom | Refraktärt kutant T-cell non-Hodgkin lymfomFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande kutant T-cell non-Hodgkin lymfom | Steg I Kutant T-cell non-Hodgkin lymfom | Steg II Kutant T-cell non-Hodgkin lymfomFörenta staterna
-
Stanford UniversityNational Institutes of Health (NIH); AmgenAvslutadLymfom, icke-Hodgkin | Lymfom: Non-Hodgkin | Lymfom: Icke-Hodgkin perifer T-cell | Lymfom: Non-Hodgkin kutant lymfom | Lymfom: Non-Hodgkin Diffus Stor B-cell | Lymfom: Non-Hodgkin follikulära / indolenta B-cell | Lymfom: Non-Hodgkin Mantle Cell | Lymfom: Non-Hodgkin Marginal Zone | Lymfom: Non-Hodgkin...Förenta staterna
-
Novartis PharmaceuticalsAvslutadMelanom | Trippel negativ bröstcancer | Anaplastisk sköldkörtelcancer | Andra fasta tumörer | Non-small Sell Lung Cancer (NSCLC)Förenta staterna, Italien, Spanien, Ungern, Taiwan, Tyskland, Nederländerna, Frankrike, Norge, Polen, Thailand, Libanon, Kalkon, Kanada
-
John ReneauAktiv, inte rekryterandeÅterkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Steg III kutant T-cell non-Hodgkin lymfom | Steg IV Kutant T-cell non-Hodgkin lymfom | Primärt kutant anaplastiskt storcelligt lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom | Lymfomatoid... och andra villkorFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)AvslutadAnaplastiskt storcelligt lymfom | Återkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfomFörenta staterna
-
Walter HanelRekryteringÅterkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Refraktärt anaplastiskt storcelligt lymfom | T-cell non-Hodgkin lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom och andra villkorFörenta staterna
-
National Cancer Institute (NCI)RekryteringRefraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande transformerat non-Hodgkin-lymfom | Återkommande non-Hodgkin lymfom | Refraktärt non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant... och andra villkorFörenta staterna
-
Mayo ClinicHar inte rekryterat ännuIndolent B-cell non-Hodgkin lymfom | Återkommande indolent non-Hodgkin-lymfom | Refraktärt indolent non-Hodgkin-lymfom | Återkommande indolent B-cell non-Hodgkin lymfom | Refraktärt indolent B-cell non-Hodgkin lymfomFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadÅterkommande Hodgkin-lymfom | Refraktärt Hodgkin-lymfom | Refraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfomFörenta staterna
Kliniska prövningar på cis-diamminedichloroplatinum
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... och andra samarbetspartnersAvslutad
-
Roswell Park Cancer InstituteAvslutadSteg IIIB Icke-småcellig lungcancer | Steg IV icke-småcellig lungcancer | Steg IV Mjukvävnadssarkom för vuxna | Metastatisk malign neoplasm i lunganFörenta staterna
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RekryteringSkivepitelcancer i huvud och nacke | Steg III Hypofarynxkarcinom AJCC v8 | Steg III Larynxcancer AJCC v8 | Steg III Läpp- och munhålscancer AJCC v8 | Steg III Orofaryngeal (p16-negativ) karcinom AJCC v8 | Hypofarynx skivepitelcancer | Laryngeal skivepitelcancer | Steg IVA Läpp- och munhålscancer AJCC... och andra villkorFörenta staterna
-
Roswell Park Cancer InstituteRekryteringKolorektal cancer | Metastatisk ooperabelt sarkom | Metastatisk malign neoplasm i lungan | Resektabelt sarkom | Metastaserande mjukdelssarkom | Metastaserande bensarkomFörenta staterna
-
Kafrelsheikh University1-Foshan University Laboratory of Emerging Infectious Disease Institute... och andra samarbetspartnersHar inte rekryterat ännu
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)AvslutadSteg III vulvarcancer | Steg IVB Vulvarcancer | Vulva skivepitelcancerFörenta staterna
-
BioCis Pharma LtdAvslutad
-
University of NebraskaNational Cancer Institute (NCI); Adherex Technologies, Inc.AvslutadAdenokarcinom i bukspottkörteln | Metastaserande bukspottkörteladenokarcinom | Steg III Bukspottkörtelcancer | Steg IVA Pankreascancer | Steg IVB Bukspottkörtelcancer | Steg IIIA Gallblåscancer | Steg IIIB Gallblåscancer | Steg IVA Gallblåscancer | Steg IVB Gallblåscancer | Gallblåsan Adenocarcinom | Ampulla... och andra villkorFörenta staterna
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastaserande kolangiokarcinom | Ooperabelt kolangiokarcinom | Avancerat kolangiokarcinomFörenta staterna
-
GOG FoundationNational Cancer Institute (NCI)Aktiv, inte rekryterandeAdenokarcinom i livmoderhalsen | Adenosquamous karcinom i livmoderhalsen | Livmoderhalscancer skivepitel, ej specificerat på annat sätt | Steg IIA Livmoderhalscancer AJCC v7 | Steg IB livmoderhalscancer AJCC v6 och v7 | Steg I livmoderhalscancer AJCC v6 och v7 | Steg IA Livmoderhalscancer AJCC v6...Förenta staterna, Korea, Republiken av, Japan